Jeffrey N. Meshulam
President chez Profectus BioSciences, Inc.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| John H. Eldridge | M | - |
Profectus BioSciences, Inc.
 Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD.
State University of New York at Buffalo
| 20 ans |
| William A. Haseltine | M | 79 |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| Frederick C. Tecce | M | 86 |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| M. G. Sarngadharan | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| Michael A. Egan | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | 16 ans |
| David Karl Clarke | M | 69 |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | 16 ans |
| Alan M. Gordon | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | 14 ans |
| Michael I. Greenebaum | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| Terry Lierman | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| Marc Tremblay | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | 16 ans |
| Steve Udem | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| Andrew Murdin | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Thomas Gerard Lynch | M | 67 |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | 14 ans |
| Shawn O'Brien | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | 2 ans |
| Craig Shular | M | 71 |
State University of New York at Buffalo
| 6 ans |
| Douglas Reif | M | 70 |
State University of New York at Buffalo
| 6 ans |
| Glenn Henrickson | M | - |
State University of New York at Buffalo
| 5 ans |
| Gary P. Jacobi | M | - |
State University of New York at Buffalo
| 5 ans |
| Glenn I. Henricksen | M | 64 |
State University of New York at Buffalo
| 6 ans |
| David A. Dooley | M | - |
State University of New York at Buffalo
| 5 ans |
| James Daly | M | 62 |
State University of New York at Buffalo
| 6 ans |
| Harry Patrick Barnum | M | - |
State University of New York at Buffalo
| 5 ans |
| Harold C. Smith | M | - |
State University of New York at Buffalo
| 5 ans |
| Donald Caldwell | M | 77 |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| Francis J. Boggan | M | - |
State University of New York at Buffalo
| 4 ans |
| D. Bruce Johnstone | M | - |
State University of New York at Buffalo
| 9 ans |
| Andrew B. Rosengard | M | - |
State University of New York at Buffalo
| 4 ans |
| Jordan Levy | M | 68 |
State University of New York at Buffalo
| 4 ans |
| James P. Griffin | M | - |
State University of New York at Buffalo
| 4 ans |
| Louis G. Henry | M | - |
State University of New York at Buffalo
| 4 ans |
| Jamilus bin Mohamed Hussin | M | 80 |
State University of New York at Buffalo
| 1 ans |
| Kevin Centofanti | M | 64 |
State University of New York at Buffalo
| 6 ans |
| Gary M. Stott | M | - |
State University of New York at Buffalo
| 2 ans |
| W. Anthony Sandonato | M | - |
State University of New York at Buffalo
| 4 ans |
| Ronald Lifton | M | 65 |
State University of New York at Buffalo
| 4 ans |
| Stuart Loewenstein | M | 64 |
State University of New York at Buffalo
| 4 ans |
| Harvey L. Kaminski | M | - |
State University of New York at Buffalo
| 3 ans |
| Jim Badke | M | - |
State University of New York at Buffalo
| 4 ans |
| Lewis I. Goldman | M | - |
State University of New York at Buffalo
| 3 ans |
| Gary Zieziula | M | 69 |
State University of New York at Buffalo
| 4 ans |
| Howard A. Werman | M | - |
State University of New York at Buffalo
| 3 ans |
| Timothy Fouts | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| Sunny Chukwudi Obidegwu | M | - |
State University of New York at Buffalo
| 4 ans |
| John Brodfuehrer | M | 66 |
State University of New York at Buffalo
| 4 ans |
| Jeffrey Robert Paul | M | - |
State University of New York at Buffalo
| 2 ans |
| Siu Kin Fok | M | 70 |
State University of New York at Buffalo
| 4 ans |
| Bob Schorr | M | - |
State University of New York at Buffalo
| 3 ans |
| Todd N. Tipton | M | 67 |
State University of New York at Buffalo
| 4 ans |
| Joel C. Schneider | M | 64 |
State University of New York at Buffalo
| 4 ans |
| Perry Edward Atkins | M | - |
State University of New York at Buffalo
| 4 ans |
| Alan F. Joslyn | M | 65 |
State University of New York at Buffalo
| 4 ans |
| Tony Ogorek | M | - |
State University of New York at Buffalo
| 1 ans |
| Richard Rosenblum | M | 65 |
State University of New York at Buffalo
| 4 ans |
| James Nish | M | 65 |
State University of New York at Buffalo
| 4 ans |
| Kim Wolin | F | 68 |
State University of New York at Buffalo
| 4 ans |
| Alvi Abuaf | M | - |
State University of New York at Buffalo
| 2 ans |
| Thomas G. Paese | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| Richard Gluck | M | - |
State University of New York at Buffalo
| 4 ans |
| Peter Jerome Grogan | M | - |
State University of New York at Buffalo
| 3 ans |
| Curt Launer | M | 68 |
State University of New York at Buffalo
| 4 ans |
| Mark Sieczkarek | M | 69 |
State University of New York at Buffalo
| 4 ans |
| Frederick Muto | M | 70 |
State University of New York at Buffalo
| 4 ans |
| David Oppenheimer | M | 67 |
State University of New York at Buffalo
| 4 ans |
| Jim Ferrare | M | - |
State University of New York at Buffalo
| 4 ans |
| Rod A. Ferguson | M | 67 |
State University of New York at Buffalo
| 3 ans |
| Lewis Marks | M | 73 |
State University of New York at Buffalo
| 3 ans |
| Chi K. Eng | M | 64 |
State University of New York at Buffalo
| 4 ans |
| Michael Calise | M | - |
State University of New York at Buffalo
| 4 ans |
| Gary E. Bie | M | - |
State University of New York at Buffalo
| 4 ans |
| Joseph I. Rader | M | - |
State University of New York at Buffalo
| 4 ans |
| Martin J. Sumner | M | - |
State University of New York at Buffalo
| 4 ans |
| Keith Blakely | M | - |
State University of New York at Buffalo
| 4 ans |
| James M. Craig | M | 67 |
State University of New York at Buffalo
| 4 ans |
| Robert Black | M | 65 |
State University of New York at Buffalo
| 4 ans |
| Sherwood Klein | M | - |
State University of New York at Buffalo
| 4 ans |
| Joseph F. Berardino | M | 73 |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | 4 ans |
| David M. Ascher | M | - |
State University of New York at Buffalo
| 3 ans |
| Evan G. Dick | M | 72 |
State University of New York at Buffalo
| 3 ans |
| Stewart Greenebaum | M | - |
Profectus BioSciences, Inc.
Profectus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD. | - |
| Marc Tipermas | M | 76 |
State University of New York at Buffalo
| 2 ans |
| Jack Ross | M | 67 |
State University of New York at Buffalo
| 4 ans |
| Marc E. Shapiro | M | 67 |
State University of New York at Buffalo
| 4 ans |
| Richard A. Denmon | M | - |
State University of New York at Buffalo
| 3 ans |
| Paul S. Molnar | M | 68 |
State University of New York at Buffalo
| 4 ans |
| Andreas Polydoros | M | - |
State University of New York at Buffalo
| 1 ans |
| Alan Cohen | M | 63 |
State University of New York at Buffalo
| 4 ans |
| Joe Frandina | M | - |
State University of New York at Buffalo
| 4 ans |
| John S. Malanowski | M | - |
State University of New York at Buffalo
| 4 ans |
| Stephen L. Giroux | M | - |
State University of New York at Buffalo
| 4 ans |
| Eric Lynn | M | - |
State University of New York at Buffalo
| 4 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 90 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jeffrey N. Meshulam
- Réseau Personnel
